It is also possible that the large inter-individual variability in the LDL-C response to a given dose of statins or PCSK9 inhibitors seen in different individuals may be caused to some extent by the genetic differences causing the FH phenotype in monogenic patients compared to those with polygenic hypercholesterolemia. The gene discussed is PCSK9; the disease is Hypercholesterolemia.